Author

Zaile Zhuang

Stanford MedicineORCID 0000-0002-3294-5805Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Athina Zerva· 2 shared James CheniD· 2 shared Martin P. SchwalmiD· 2 shared Nicolai D. RaigiD· 2 shared Riley K. TogashiiD· 2 shared Stefan KnappiD· 2 shared Thomas HankeiD· 2 shared Andreas Kraemer· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Athina Zerva

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Small-molecule modulators of HIPK4 activity and proteostasis

Zaile Zhuang, Riley K. Togashi, Patrick C. Kearney, Ian Pass, Steven M. Swick, Fu‐Yue Zeng, Andrey A. Bobkov, Lynn Miya Fujimoto, Shubhankar Dutta, Athina Zerva, Nicolai D. Raig, Debasmita Saha, Atoosa Emami, Martin P. Schwalm, Bradley K. Moon, , James Chen

This study identifies cyanoquinoline-based HIPK4 inhibitors with nanomolar potency and reveals their cell-type-specific effects on HIPK4 proteostasis and autophagy.

Journal of the American Chemical Society · Oct 5, 2026Peer-reviewedBiochemistry

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137

Athina Zerva, Nicolai D. Raig, Zaile Zhuang, Andreas Kraemer, Johannes Dopfer, Riley K. Togashi, Martin P. Schwalm, Lewis Elson, Julia Marie Frischkorn, Benedict‐Tilman Berger, Susanne Müller, James Chen, Stefan Knapp, Thomas Hanke

The paper describes the development of AZ137, a potent and selective HIPK4 inhibitor derived from bosutinib, and validates its utility as a tool for studying HIPK4's biological functions.

Journal of Medicinal Chemistry · Aug 18, 2026Peer-reviewedBiochemistry